dr. goldman on targeted therapy options for egfr-, alk-, and ros1-mutated nsclc
Published 4 years ago • 217 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
6:30
treatment options for alk/ros1 mutation
-
5:53
targeted therapy in non-small cell lung cancer
-
1:32
dr. goldman on the use of immunotherapy in oncogene-driven nsclc
-
4:41
upfront egfr-targeted therapy for nsclc
-
4:07
chemotherapy with i-o therapy in egfr- or alk-mutated nsclc
-
4:05
the evolution of alk/ros1-targeted therapy in nsclc
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
8:25
egfr & alk/ros1 testing in squamous nsclc
-
6:44
treatment options for lung cancer mutations & contingencies
-
2:00
dr. goldberg on sequencing following treatment with osimertinib in nsclc
-
1:22
dr. lam discusses agents for ros1-mutated nsclc
-
2:34
goldman: rociletinib in egfr-mutated nsclc
-
1:27
targeted therapies show activity in ros1 fusion-positive lung cancer
-
5:50
targeted therapy in egfr exon 20-mutant non–small cell lung cancer
-
4:49
emerging alk/ros1 tkis for nsclc
-
4:43
upfront therapy for alk/ros1-rearranged nsclc
-
1:10
dr. gubens on prevalence of egfr/alk/ros1 and pd-l1 expression in nsclc
-
1:45
dr. feliciano on ros1-targeted therapy in nsclc
-
1:36
dr. drilon on targeted therapies for patients with ros1-rearranged lung cancer